Objective To analyse the results of an action research process, the aim of which is to involve patients in fundamental psychiatric genomics research, against theoretical backgrounds that formulate a Dialogue Model for patient involvement.Background Mixed views continue to exist about the value, appropriateness and potential of involving consumers and patients in basic medical research. There is a need to learn from practical examples.

Client participation in elderly care organizations requires shifting traditional power relations and establishing communicative action that involves the lifeworlds of clients and professionals alike. This article describes a particular form of client participation in which one client was part of a team of professionals in a residential care home. Their joint remit was to plan the implementation of a new personal care file for residents. We describe the interactions within this team through an ethnodrama, based on participant observations and the embodied presence of the researcher (first author). The narratives and voices of all team members are dramatized in this ethnodrama. Throughout the project the team members experienced confusion relating to the confrontation between lifeworld and system, as experienced by the client and professionals in the team. We analyze these tensions by making use of a Habermasian theoretical framework. We conclude that forms for collective client participation in residential care homes should be developed based on communicative action between clients and professionals, with room for emotional engagement.

No abstract

Psychiatric genomics is made in practice. Developments in psychiatric genomics are the result of an open, contingent process in which different stakeholders -scientists, policymakers, professionals and patients -are involved. This article examines the practices and perspectives of scientists in two long-term, large-scale Dutch psychiatric research consortia that are mapping the origin and development of psychosis, anxiety and depression. The article also explores the perspectives of the funding agency and patients and patient organizations that are in contact with the research consortium on psychoses. What are the issues and concerns of scientists involved in psychiatric genomics, what do they expect genomics will mean for psychiatry, what kind of research are they conducting? What are the issues, concerns and expectations of the main funding agency? How do patients and patient organizations regard developments in psychiatric genomics, and how do they relate to the ongoing research? The conclusion is that different psychiatric futures -not necessarily resulting in geneticized disorders -may emerge from multiple developments in the field. Developments in this case study appear to be contingent on international developments in scientific research; on scientists' different perspectives of what psychiatric disorders are; on national and European traditions in psychiatry, and on the input of patients and patient organizations into research.